دولاجلوتيد: الفرق بين النسختين

 

'''دولاجلوتيد''' {{إنج|Dulaglutide}} هو [[دواء]] يُستعمل في [[علاج (طب)|علاج]]:<ref name="pmid24742660">{{cite journal |vauthors=Nauck M, Weinstock RS, Umpierrez GE, Guerci B, Skrivanek Z, Milicevic Z |title=Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5) |journal=Diabetes Care |volume=37 |issue=8 |pages=2149–58 |date=August 2014 |pmid=24742660 |doi=10.2337/dc13-2761 |url=http://care.diabetesjournals.org/content/37/8/2149.full |accessdate=2015-03-01 |pmc=4113177| مسار الأرشيف = https://web.archive.org/web/20190611163058/http://care.diabetesjournals.org/content/37/8/2149.full | تاريخ الأرشيف = 11 يونيو 2019 }}</ref><ref name="pmid24918645">{{cite journal |author=Amblee A |title=Dulaglutide for the treatment of type 2 diabetes |journal=Drugs Today |volume=50 |issue=4 |pages=277–89 |date=April 2014 |pmid=24918645 |doi=10.1358/dot.2014.50.4.2132740 |url=}}</ref><ref>{{cite journal|last1=Liu|first1=J|last2=Li|first2=L|last3=Deng|first3=K|last4=Xu|first4=C|last5=Busse|first5=JW|last6=Vandvik|first6=PO|last7=Li|first7=S|last8=Guyatt|first8=GH|last9=Sun|first9=X|title=Incretin based treatments and mortality in patients with type 2 diabetes: systematic review and meta-analysis.|journal=BMJ (Clinical research ed.)|date=8 June 2017|volume=357|pages=j2499|pmid=28596247|doi=10.1136/bmj.j2499|pmc=5463186}}</ref>

|doi =10.5281/ZENODO.1435999

}}</ref>

*[[اختلال تحمل الجلوكوز]]<ref name="مولد تلقائيا1" />

==دوره==

|تاريخ الوصول = 15 مارس 2018

* [[خافضات سكر الدم]]

 

==المراجع==

{{مراجع}}

{{إخلاء مسؤولية طبية}}

{{شريط بوابات|الكيمياء الحيوية|صيدلة|طب}}